Cite
HARVARD Citation
Geerdink, L. et al. (2017). First-in-child use of the oral selective prostacyclin IP receptor agonist selexipag in pulmonary arterial hypertension. Pulmonary circulation. pp. 551-554. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Geerdink, L. et al. (2017). First-in-child use of the oral selective prostacyclin IP receptor agonist selexipag in pulmonary arterial hypertension. Pulmonary circulation. pp. 551-554. [Online].